港股抗疫概念股集體拉昇,山東新華製藥漲超7%,專家稱6月底或是今年新冠第二波高峯
5月23日港股開盤,抗疫概念股集體拉昇,山東新華製藥股份漲超7%,開拓藥業、康希諾生物漲超6%,三葉草生物漲超5%。
消息面上,5月22日,鍾南山在2023大灣區科學論壇生物醫藥與健康分論壇上表示,基於SEIRS模型的預測顯示,全國2023年新冠第二波疫情主要是奧密克戎XBB系列毒株引發的,4月中旬起峯,5月底會出現一個波峯,感染人數將達到約4000萬/周,高峯發生在6月底,將達到6500萬/周。
他表示,研發針對XBB變異株有更好保護能力的疫苗非常重要,並透露目前已經有兩種針對XBB的疫苗被初步批準,還有三四種很快能被批準。
有機構此前表示,隨着第二輪新冠感染高峯可能到來的預期不斷加強,建議從檢測、預防、治療等角度切入佈局新冠產業鏈機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.